765
Views
13
CrossRef citations to date
0
Altmetric
Research Article

Results of treatment with azacitidine in patients aged ≥ 75 years included in the Spanish Registry of Myelodysplastic Syndromes

, , , , , , , , , , , , , , , , , , , , , , , , , , , , , , & show all
Pages 1300-1303 | Received 03 Apr 2013, Accepted 08 Aug 2013, Published online: 16 Sep 2013

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (4)

Walid Macaron, Zaven Sargsyan & Nicholas J. Short. (2022) Hyperleukocytosis and leukostasis in acute and chronic leukemias. Leukemia & Lymphoma 63:8, pages 1780-1791.
Read now
Yufang Wang, Chunrong Chen, Yanfang Lin, Meihua Chen, Jinxiang Cai, Xiujuan Chen, Saizhen Chen, Xiaomei Huang & Yanjuan Lin. (2022) Polyurethane foam dressings ameliorating local adverse effects of azacitidine: a randomized controlled trial. Leukemia & Lymphoma 63:3, pages 703-709.
Read now
Laura S. McDonald, Peter McCarthy, Mohammad Khan, Patrick Hogan, Eileen Kelleher, Philip T. Murphy, John Quinn, Ronan Desmond, John McHugh, Melanie Strickland, Elizabeth O'Connell, Mary Cahill, Su W. Maung, Clodagh Keohane, Desmond O'Neill, Dan Ryan, Vitaliy Mykytiv & Helen Enright. (2019) A multicenter report on the natural history of myelodysplastic syndromes in very old patients (aged over 85 years). Leukemia & Lymphoma 60:5, pages 1324-1327.
Read now
Massimo Breccia, Matteo Molica, Irene Zacheo & Giuliana Alimena. (2014) Azacitidine for myelodysplastic patients aged > 65 years: a review of clinical efficacy. Expert Opinion on Pharmacotherapy 15:11, pages 1621-1630.
Read now

Articles from other publishers (9)

Iván Martín, Blanca Navarro, Alicia Serrano, Eva Villamón, Marisa Calabuig, Carlos Solano, Felipe Javier Chaves, Nuria Yagüe, Maribel Orts, Paula Amat, Azahara Fuentes, Enrique Seda, Francisca García, Juan Carlos Hernández-Boluda & Mar Tormo. (2020) Impact of clinical features, cytogenetics, genetic mutations, and methylation dynamics of CDKN2B and DLC-1 promoters on treatment response to azacitidine. Annals of Hematology 99:3, pages 527-537.
Crossref
Rory M. Shallis & Amer M. Zeidan. (2018) More is less, less is more, or does it really matter? The curious case of impact of azacitidine administration schedules on outcomes in patients with myelodysplastic syndromes. BMC Hematology 18:1.
Crossref
Roman M. Shapiro & Alejandro Lazo-Langner. (2018) Systematic review of azacitidine regimens in myelodysplastic syndrome and acute myeloid leukemia. BMC Hematology 18:1.
Crossref
Anna Schuck, Marie-Christine Goette, Judith Neukirchen, Andrea Kuendgen, Norbert Gattermann, Thomas Schroeder, Guido Kobbe, Ulrich Germing & Rainer Haas. (2017) A retrospective study evaluating the impact of infectious complications during azacitidine treatment. Annals of Hematology 96:7, pages 1097-1104.
Crossref
Vasiliki Pappa, Achilles Anagnostopoulos, Eleni Bouronikou, Evangelos Briasoulis, Ioannis Kotsianidis, Maria Pagoni, Panagiotis Zikos, Konstantinos Tsionos, Nora Viniou, John Meletis, Helen Papadaki, Anna Kioumi, Athanasios Galanopoulos, Elisavet-Christine Vervessou, Elias Poulakidas, Panagiotis Karmas, Kiki Karvounis & Argiris Symeonidis. (2016) A retrospective study of azacitidine treatment in patients with intermediate-2 or high risk myelodysplastic syndromes in a real-world clinical setting in Greece. International Journal of Hematology 105:2, pages 184-195.
Crossref
Heidi D. Klepin. (2016) Myelodysplastic Syndromes and Acute Myeloid Leukemia in the Elderly. Clinics in Geriatric Medicine 32:1, pages 155-173.
Crossref
E. Tseng, A. Prica, L. Zhang, N. Mittmann, S. J. Seung, J. Callum, T. Kim, R. A. Wells & R. Buckstein. (2015) Monthly blood transfusions decrease after four months of azacitidine. Vox Sanguinis 109:2, pages 163-167.
Crossref
Renata Lukackova, Maria Gerykova Bujalkova, Lubica Majerova & Beata Mladosievicova. (2014) Molecular genetic methods in the diagnosis of myelodysplastic syndromes. A review. Biomedical Papers 158:3, pages 339-345.
Crossref
Akari Hashimoto, Kohichi Takada, Hiroto Horiguchi, Tsutomu Sato, Satoshi Iyama, Kazuyuki Murase, Yusuke Kamihara, Kaoru Ono, Ayumi Tatekoshi, Tsuyoshi Hayashi, Koji Miyanishi, Yasushi Sato, Tomohisa Furuhata, Masayoshi Kobune, Rishu Takimoto, Koichi Hirata & Junji Kato. (2014) Combination Chemotherapy of Azacitidine and Cetuximab for Therapy-Related Acute Myeloid Leukemia following Oxaliplatin for Metastatic Colorectal Cancer. Case Reports in Oncology 7:2, pages 316-322.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.